Signs and symptoms of ocular surface status in glaucoma patients switched from timolol 0.5% to brinzolamide 1%/timolol 0.5% fixed combination: a 6-month efficacy and tolerability, multicenter, open-label prospective study

Bibliography

• EGS. Terminology and guidelines for glaucoma. 3rd edition. Dogma, Savona; 2008. p. 14-21
   Google Scholar
• Risk factors for progression of visual field abnormalities in normal tension glaucoma. Collaborative normal tension glaucoma study group. Am J Ophthalmol 2001;131:699-708
   PubMed Web of Science ®Google Scholar
• Leske MC, Heijl A, Hyman L, Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology 2007;114:1965-72
   PubMed Web of Science ®Google Scholar
• The ocular hypertension treatment study. A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of POAG. Arch Ophthalmol 2002;120:701-3
   PubMedGoogle Scholar
• European glaucoma prevention study. Development of primary open angle glaucoma in individuals with ocular hypertension. Ophthalmology 2007;114:10-19
   PubMedGoogle Scholar
• AGIS investigators: the Advanced Glaucoma Intervention Study (AGIS):14. Baseline risk factors for sustained loss of visual field and visual acuity in patients with advanced glaucoma. Am J Ophtalmol 2002;134:499-512
   PubMed Web of Science ®Google Scholar
• Hollo G. Brinzolamide/timolol fixed combination for open-angle glaucoma and ocular hypertension. Expert Rev Ophthalmol 1009;4:129-33
   Google Scholar
• Manni G, Denis P, Chew P, The safety and efficacy of brinzolamide 1%/timolol 0,5% fixed combination versus Dorzolamide 2%/timolol 0,5% in patients with open angle glaucoma or ocular hypertension. J Glaucoma 2009;18:293-300
   PubMed Web of Science ®Google Scholar
• Vold SD, Evans RM, Stewart RH, ; brinzolamide/timolol Comfort Study Group. A One-Week Comfort Study of BID-Dosed brinzolamide 1%/timolol 0.5% Ophthalmic Suspension Fixed Combination Compared to BID-Dosed Dorzolamide 2%/timolol 0.5% Ophthalmic Solution in Patients with Open-Angle Glaucoma or Ocular Hypertension. J Ocul Pharmacol Ther 2008;24:601-5
   PubMed Web of Science ®Google Scholar
• Mundorf TK, Rauchman SH, Williams RD, ; brinzolamide/timolol Preference Study Group. A patient preference comparison of Azarga™ (brinzolamide/timolol fixed combination) vs Cosopt® (dorzolamide/timolol fixed combination) in patients with open-angle glaucoma or ocular hypertension. Clin Ophthalmol 2008;2:623-8
   PubMedGoogle Scholar
• Lee BL, Gutierrez P, Gordon M, The Glaucoma Symptom Scale- A Brief Index of Glaucoma-Specific Symptoms. Arch Ophthalmol 1998;116:861-6
   PubMed Web of Science ®Google Scholar
• Nichols KK, Nichols JJ, Zadnik K. Frequency of dry eye diagnostic test procedures used in various modes of ophthalmic practice. Cornea 2000;19:477-82
   PubMed Web of Science ®Google Scholar
• Pflugfelder SC, Tseng SC, Sanabria O, Evaluation of subjective assessment and objective diagnostic tests for diagnosing tear-film disorders known to cause ocular irritation. Cornea 1998;17:38-56
   PubMed Web of Science ®Google Scholar
• Bron AJ, Evans VE, Smith JA. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea 2003;22:640-9
   PubMed Web of Science ®Google Scholar
• Jampel HD, Schwartz GF, Robin AL, Abrams DA. Patient preferences for eye drop characteristics. A willingness to pay analysis. Arch Ophthalmol 2003;121:540-6
   PubMed Web of Science ®Google Scholar
• Kaback M, Scoper SV, Arzeno G, Intraocular pressure-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination compared with brinzolamide 1% and timolol 0.5%. Ophthalmology 2008;115:1728-34
   PubMed Web of Science ®Google Scholar
• Beckers HJM, Schouten JS, Webers CA. Role of fixed-combination brinzolamide1%/timolol 0.5% in the treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension. Clin Ophthalmol 2009;3:593-9
   PubMedGoogle Scholar
• Baudouin C, de Lunardo C. Short term comparative study of topical 2% cartelol with and without benzalkonium chloride in healthy volunteers. Br J Ophthalmol 1998;82:39-42
   PubMed Web of Science ®Google Scholar
• Xiong C, Chen D, Liu J, A rabbit model induced by topical medication of a preservative Benzalkonium Chloride. Invest Ophthalmol Vis Sci 2008;49:1850-6
   PubMed Web of Science ®Google Scholar
• Rossi GCM, Tinelli C, Pasinetti GM, Dry eye syndrome-related quality of life in glaucoma patients. Eur J Ophthalmol 2009;4:572-9
   Google Scholar
• Guenoun JM, Badouin C, Rat P, In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells. Invest Ophthalmol Vis Sci 2005;46:2444-50
   PubMed Web of Science ®Google Scholar
• Stewart WC, Holmes KT, Johnson MA. Washout periods for brimonidine 0.2% and latanoprost 0.005%. Am J Ophthalmol 2001;131:798-9
   PubMed Web of Science ®Google Scholar